CX-2009 (CD166-directed Probody drug conjugate)
The company is current enrolling patients in the PROCLAIM-CX-2009 study, a Phase 1/2 clinical trial evaluating CX-2009 as monotherapy in patients with select advanced solid tumors, including breast cancer, castration-resistant prostate cancer, cholangiocarcinoma (bile duct cancer), endometrial cancer, head and neck cancer, non-small-cell lung cancer and ovarian cancer.
While CD166 is widely and highly expressed on solid tumor cells, it has been previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates targeting CD166 have led to complete regressions in models of breast and lung cancer at therapeutically relevant doses, and are well tolerated in non-human primates. CX-2009 has been conjugated with DM4, a highly potent cytotoxic drug. DM4 is developed by and licensed from ImmunoGen.